Insulet Climbs to 405th in Trading Volume Amid 'Moderate Buy' Consensus and Elevated Valuation Risks

On September 2, 2025, Insulet (NASDAQ:PODD) saw a surge in trading activity, with a volume of $0.27 billion, marking a 55.41% increase from the previous day. The stock ranked 405th in trading volume, reflecting heightened investor interest.

Analyst sentiment remains cautiously optimistic, with a "Moderate Buy" consensus rating based on 16 buy and 2 hold recommendations from 18 research reports over the past 90 days. Earnings are projected to grow by 26.79% annually, though the stock’s price-to-earnings (P/E) ratio of 104.84 exceeds the medical sector average of 82.65, signaling potential overvaluation relative to peers.

Short interest in Insulet has risen by 2.29% month-on-month, with 2.54% of shares sold short. The short interest ratio stands at 2.5 days to cover, indicating manageable but slightly elevated bearish pressure. Institutional activity has been mixed, with recent purchases by entities like Corebridge Financial and OMERS, while others, including Credit Agricole, have reduced stakes.

Leadership changes at the company, including the promotion of Eric Benjamin to COO, and a price target upgrade from Barclays to $300, have drawn attention. Institutional transactions and analyst optimism suggest ongoing strategic confidence, though valuation metrics highlight the need for cautious assessment of growth potential.